Project Grant K99CA293142
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$169K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $132,462 to the Fred Hutchinson Cancer Center in Seattle, WA to support research aimed at improving engineered T cell receptor T cell (TCR-T) therapy for solid tumors. The key objectives are to: 1) Determine why TCR-T cells form a different reservoir of stem-like progenitor cells in tumor-draining lymph nodes compared to endogenous tumor-specific T cells, and 2)...
This Project Grant award, titled "A NOVEL IMMUNOTHERAPY FOR PANCREATIC CANCER USING MICRO-RNA-29A," was provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) to the University of Miami in the amount of $107,948. The award will support research to determine the contribution of the TNFR2-miR-29a axis to CD8 T cell dysfunction in pancreatic ductal adenocarcinoma (PDAC), with the goal of generating durable T-cell mediated anti-tumor activity. The...
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...
The National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) grant program, awarded a $138,742 Project Grant to The Johns Hopkins University on September 20, 2024. The grant supports a research project titled "Investigation of Immunotherapy-Induced Alterations to Cellular Communication Networks in Pancreatic Ductal Adenocarcinoma." The key objectives are to utilize single-cell RNA sequencing data to: 1) develop statistical methods to identify cellular...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) in the amount of $356,732 supports research to characterize the role of CCR6+ regulatory T cells (Tregs) in the immunosuppressive tumor microenvironment of pancreatic cancer. The awardee, The Medical College of Wisconsin, Inc., will use in vitro and in vivo models to investigate how the CCR6-CCL20 signaling axis shapes the function of these "super suppressor" Tregs and impacts...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $293,369 to Duke University to conduct research on mechanisms of macrophage-mediated immune evasion in residual tumors. The research aims to uncover potential strategies to target and engineer the immune-mediated clearance of residual tumor cells that can lead to cancer relapse, even after initial response to oncogene-targeted therapies. The award period runs from Aug 1, 2024 to Mar 31,...
This Project Grant award of $162,486 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at the University of Pittsburgh to investigate the functional consequences of high glucose culture on adoptive T cell therapies for cancer. The key objectives are to: (1) identify cellular proteins that are differentially O-GlcNAcylated in high glucose conditions and determine if inhibiting O-GlcNAcylation can restore T cell cytokine production, antitumor immunity,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 in funding to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in patients with metastatic pancreatic cancer. The study aims to assess the clinical outcomes of combining MT-601 with frontline FOLFIRINOX chemotherapy,...
This Project Grant award, valued at $148,568.00, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant supports research by Dr. Adrianne Wallace-Povirk, a postdoctoral fellow at the Fred Hutchinson Cancer Center, to explore the molecular mechanisms controlling CDK7 inhibitor sensitivity in pancreatic ductal adenocarcinoma (PDA). The research aims to: (1) identify how the SIRT6 tumor suppressor affects ATF4 stability,...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $127,049 to President and Fellows of Harvard College, doing business as Harvard Medical School, to investigate the functional and spatial properties of tumor-specific tumor-infiltrating CD8 T cells. The research aims to better understand the determinants of T cell responses against tumors and the relative importance of antigen class, particularly neoantigens and...